Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Conditions

• Recurrent Glioma
• Recurrent WHO Grade 2 Glioma
• Recurrent WHO Grade 3 Glioma
• Recurrent WHO Grade 4 Glioma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Biospecimen Collection — PROCEDURE
  Undergo collection of blood and/or tissue samples
• Erdafitinib — DRUG
  Given PO
• Magnetic Resonance Imaging — PROCEDURE
  Undergo MRI
• Optical Coherence Tomography — PROCEDURE
  Undergo OCT

Study Details

This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals tumor cells to multiply. This may help keep tumor cells from growing and may kill them. Giving erdafitinib may help to slow the growth of, or to shrink, tumor cells in patients with recurrent or progressive IDH-wild type gliomas with FGFR-TACC gene fusion.

Key Dates

Start date

Jan 4, 2024

Status verified

Mar 2026

Primary completion

Oct 23, 2026

Completion

Oct 23, 2026

Study Design

Enrollment

30 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (erdafitinib)
  Patients receive erdafitinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI, OCT, and collection of blood samples throughout the trial. Additionally, patients may optionally undergo collection of tissue samples on study.

Primary Outcome Measure

Objective response rate [ Time Frame: Up to 2 years ]

Locations (27)

Find similar trials in Aurora, CO

Related Studies

• Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
  PHASE2 · Recruiting · Academic and Community Cancer Research United · Scottsdale, Arizona
• PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
  Recruiting · Baptist Health South Florida · Boca Raton, Florida
• Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
  PHASE1 · Recruiting · Northwestern University · Chicago, Illinois
• A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma
  Recruiting · Mayo Clinic · Jacksonville, Florida